Friday, 19 Jul 2019

You are here

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

  • CV Risk in Gout Correlates with NETs -  A study from the Reade Amsterdam Gout cohort studied 75 gout  patients - many with chronic polyarticular (71%) and tophaceous gout (21%) – to assess if neutrophil extracellular traps (NETs) and other markers of neutrophil activation (peroxidase activity) are seen in gout patients and if NETs could be cardiovascular risk calculated for individual patients.   They convincingly showed that NETs and markers of neutrophil activation and inflammatory markers were correlated with clinical features of gout, especially in polyarticular patients.  Netosis, perioxidase activity and calprotectin levels were elevated in gout patients compared to healthy controls. ETs were also correlated with cardiovascular risk scores.  It appears this strong neutrophil activation profile adds to the cardiovascular risks experienced by gout patients. OP0300
  • MAXIMISE study: It is estimated that 10% of psoriatic arthritis (PsA) patients will have axial disease (often with HLA-B27 positivity). Secukinumab is FDA approved for both PsA and AS.  The MAXIMISE study was a 52 weeks, phase 3, RCT of secukinumab IN 498 PsA patients with axial involvement. At 12 weeks, SEC treated patients had a >60% ASAS20 using either 150mg or 300 mg every 4 weeks (after a weekly loading regimen).  Good news for another subset of PsA patients. OP0235


The author has received research/grant financial support on this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.